1
|
Koubek EJ, Buhrow SA, Safgren SL, Jia L, Goetz MP, Ames MM, Reid JM. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism. Drug Metab Dispos 2023; 51:183-192. [PMID: 36351835 PMCID: PMC9900863 DOI: 10.1124/dmd.122.000929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 08/22/2022] [Accepted: 09/16/2022] [Indexed: 11/10/2022] Open
Abstract
Endoxifen (ENDX) is an active metabolite of tamoxifen (TAM), a drug commonly used for the treatment of estrogen receptor-positive breast cancer and metabolized by CYP2D6. Genetic or drug-induced reductions in CYP2D6 activity decrease plasma ENDX concentrations and TAM efficacy. It was proposed that direct oral administration of ENDX would circumvent the issues related to metabolic activation of TAM by CYP2D6 and increase patient response. Here, we characterized the pharmacokinetics and oral bioavailability of ENDX in female rats and dogs. Additionally, ENDX exposure was compared following equivalent doses of ENDX and TAM. ENDX exposure was 100-fold and 10-fold greater in rats and dogs, respectively, with ENDX administration compared with an equivalent dose of TAM. In single-dose administration studies, the terminal elimination half-life and plasma clearance values were 6.3 hours and 2.4 L/h per kg in rats given 2 mg/kg i.v. ENDX and 9.2 hours and 0.4 L/h/kg in dogs given 0.5 mg/kg i.v. ENDX, respectively. Plasma concentrations above 0.1 µM and 1 µM ENDX were achieved with 20-mg/kg and 200-mg/kg doses in rats, and concentrations above 1 µM and 10 µM were achieved with 15-mg/kg and 100-mg/kg doses in dogs. Oral absorption of ENDX was linear in rats and dogs, with bioavailability greater than 67% in rats and greater than 50% in dogs. In repeated-dose administration studies, ENDX peak plasma concentrations reached 9 µM in rats and 20 µM in dogs following four daily doses of 200 mg/kg or 30 mg/kg ENDX, respectively. The results indicate that ENDX has high oral bioavailability, and therapeutic concentrations were maintained after repeated dosing. Oral dosing of ENDX resulted in substantially higher ENDX concentrations than a similar dose of TAM. These data support the ongoing development of ENDX to overcome the limitations associated with CYP2D6-mediated metabolism of TAM in humans. SIGNIFICANCE STATEMENT: This study presents for the first time the pharmacokinetics and bioavailability of endoxifen and three key tamoxifen metabolites following repeated oral dosing in female rats and dogs. This study reports that endoxifen has high oral bioavailability, and therapeutic concentrations were maintained after repeated dosing. On the basis of these data, Z-endoxifen (Z-ENDX) was developed as a drug based upon the hypothesis that oral administration of Z-ENDX would overcome the limitations of CYP2D6 metabolism required for full metabolic activation of tamoxifen.
Collapse
Affiliation(s)
- Emily J Koubek
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Sarah A Buhrow
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Stephanie L Safgren
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Lee Jia
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Matthew P Goetz
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Matthew M Ames
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| | - Joel M Reid
- Departments of Oncology (E.J.K., S.A.B., S.L.S., M.P.G., M.M.A., J.M.R.) and Molecular Pharmacology and Experimental Therapeutics (S.L.S., M.P.G., M.M.A., J.M.R.), Mayo Clinic, Rochester, Minnesota; and National Institutes of Health, Frederick, Maryland (L.J.)
| |
Collapse
|
2
|
Mishin V, Heck DE, Jan YH, Richardson JR, Laskin JD. Distinct effects of form selective cytochrome P450 inhibitors on cytochrome P450-mediated monooxygenase and hydrogen peroxide generating NADPH oxidase. Toxicol Appl Pharmacol 2022; 455:116258. [PMID: 36174671 DOI: 10.1016/j.taap.2022.116258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 09/14/2022] [Accepted: 09/22/2022] [Indexed: 11/16/2022]
Abstract
A characteristic of cytochrome P450 (CYP) enzymes is their ability to generate H2O2, either directly or indirectly via superoxide anion, a reaction referred to as "NADPH oxidase" activity. H2O2 production by CYPs can lead to the accumulation of cytotoxic reactive oxygen species which can compromise cellular functioning and contribute to tissue injury. Herein we determined if form selective CYP inhibitors could distinguish between the activities of the monooxygenase and NADPH oxidase activities of rat recombinant CYP1A2, CYP2E1, CYP3A1 and CYP3A2 and CYP1A1/2-enriched β-naphthoflavone-induced rat liver microsomes, CYP2E1-enriched isoniazide-induced rat liver microsomes and CYP3A subfamily-enriched dexamethasone-induced rat liver microsomes. In the presence of 7,8-benzoflavone (2.0 μM) for CYP1A2 and 4-methylpyrazole (32 μM) or DMSO (16 mM) for CYP2E1, monooxygenase activity was blocked without affecting NADPH oxidase activity for both the recombinant enzymes and microsomal preparations. Ketoconazole (1.0 μM), a form selective inhibitor for CYP3A subfamily enzymes, completely inhibited monooxygenase activity of rat recombinant CYP3A1/3A2 and CYP3A subfamily in rat liver microsomes; it also partially inhibited NADPH oxidase activity. 7,8-benzoflavone is a type I ligand, which competes with substrate binding, while 4-methylpyrazole and DMSO are type II heme binding ligands. Interactions of heme with these type II ligands was not sufficient to interfere with oxygen activation, which is required for NADPH oxidase activity. Ketoconazole, a type II ligand known to bind multiple sites on CYP3A subfamily enzymes in close proximity to heme, also interfered, at least in part, with oxygen activation. These data indicate that form specific inhibitors can be used to distinguish between monooxygenase reactions and H2O2 generating NADPH oxidase of CYP1A2 and CYP2E1. Mechanisms by which ketoconazole inhibits CYP3A NADPH oxidase remain to be determined.
Collapse
Affiliation(s)
- Vladimir Mishin
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA
| | - Diane E Heck
- Department of Public Health, New York Medical College, Valhalla, NY 10595, USA
| | - Yi-Hua Jan
- Department of Environmental and Occupational Health and Justice, Rutgers University School of Public Health, Piscataway, NJ 08854, USA
| | - Jason R Richardson
- Department of Environmental Health Sciences, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA
| | - Jeffrey D Laskin
- Department of Environmental and Occupational Health and Justice, Rutgers University School of Public Health, Piscataway, NJ 08854, USA.
| |
Collapse
|
3
|
Dai Y, Luo J, Xiang E, Guo Q, He Z, Gong Z, Sun X, Kou H, Xu K, Fan C, Liu J, Qiu S, Wang Y, Wang H, Guo Y. Prenatal Exposure to Retrorsine Induces Developmental Toxicity and Hepatotoxicity of Fetal Rats in a Sex-Dependent Manner: The Role of Pregnane X Receptor Activation. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2021; 69:3219-3231. [PMID: 33685126 DOI: 10.1021/acs.jafc.0c06748] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Pyrrolizidine alkaloids (PAs) are a type of natural phytotoxin that contaminate food and feed and become an environmental health risk to humans and livestock. PAs exert toxicity that requires metabolic activation by cytochrome P450 (CYP) 3A, and case reports showed that fetuses are quite susceptible to PAs toxicity. The aim of this study was to explore the characteristics of developmental toxicity and fetal hepatotoxicity induced by retrorsine (RTS, a typcial toxic PA) and the underlying mechanism. Pregnant Wistar rats were intragastrically administered with 20 mg/(kg·day) RTS from gestation day (GD) 9 to 20. Results showed that prenatal RTS exposure lowered fetal bodyweights, reduced hepatocyte numbers, and potentiated hepatic apoptosis in fetuses, particularly females. Simutaneously, RTS increased CYP3A expression and pregnane X receptor (PXR) activation in female fetal liver. We further confirmed that RTS was a PXR agonist in LO2 and HepG2 cell lines. Furthermore, agonism or antagonism of androgen receptor (AR) either induced or blocked RTS-mediated PXR activation, respectively. As a PXR agonist, RTS toxicity was exacerbated in female fetus due to the increased CYP3A induction and self-metabolism, while the inhibitory effect of AR on PXR activation reduced the susceptibility of male fetus to RTS. Our findings indicated that PXR may be a potential therapeutic target for PA toxicity.
Collapse
Affiliation(s)
- Yongguo Dai
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Jinyuan Luo
- Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei Province, China
| | - E Xiang
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Qi Guo
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Zheng He
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Zheng Gong
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Xiaoxiang Sun
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Hao Kou
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei Province, China
| | - Kequan Xu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Chengpeng Fan
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
| | - Jie Liu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Shuaikai Qiu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Yanqing Wang
- Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei Province, China
| | - Hui Wang
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Yu Guo
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| |
Collapse
|
4
|
Female-specific activation of pregnane X receptor mediates sex difference in fetal hepatotoxicity by prenatal monocrotaline exposure. Toxicol Appl Pharmacol 2020; 406:115137. [PMID: 32682830 DOI: 10.1016/j.taap.2020.115137] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 06/21/2020] [Accepted: 07/10/2020] [Indexed: 01/06/2023]
Abstract
Pyrrolizidine alkaloids (PAs) are a group of hepatic toxicant widely present in plants. Cytochrome P450 (CYP) 3A plays a key role in metabolic activation of PAs to generate electrophilic metabolites, which is the main cause of hepatotoxicity. We have previously demonstrated the sex difference in developmental toxicity and hepatotoxicity in fetal rats exposed to monocrotaline (MCT), a representative toxic PA. The aim of this study was to explore the underlying mechanism. 20 mg·kg-1·d-1 MCT was intragastrically given to pregnant Wistar rats from gestation day 9 to 20. CYP3As expression and pregnane X receptor (PXR) activation were specifically enhanced in female fetal liver. After MCT treatment, we also observed a significant increase of CYP3As expression in LO2 cells (high PXR level) or hPXR-transfected HepG2 cells (low PXR level). Employing hPXR and CYP3A4 dual-luciferase reporter gene assay, we confirmed the agonism effect of MCT on PXR-dependent transcriptional activity of CYP3A4. Agonism and antagonism of the androgen receptor (AR) either induced or blocked MCT-induced PXR activation, respectively. This study was the first report identifying that MCT served as PXR agonist to induce CYP3A expression. CYP3A induction may increase self-metabolic activation of MCT and subsequently lead to more severe hepatotoxicity in female fetus. While in male, during the intrauterine period, activated AR by testosterone secretion from developing testes represses MCT-induced PXR activation and CYP3A induction, which may partially protect male fetus from MCT-induced hepatotoxicity.
Collapse
|
5
|
Sun Y, Wang Y, Liang B, Chen T, Zheng D, Zhao X, Jing L, Zhou X, Sun Z, Shi Z. Hepatotoxicity of decabromodiphenyl ethane (DBDPE) and decabromodiphenyl ether (BDE-209) in 28-day exposed Sprague-Dawley rats. THE SCIENCE OF THE TOTAL ENVIRONMENT 2020; 705:135783. [PMID: 31787299 DOI: 10.1016/j.scitotenv.2019.135783] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2019] [Revised: 09/23/2019] [Accepted: 11/24/2019] [Indexed: 05/22/2023]
Abstract
Decabromodiphenyl ether (BDE-209) and its substitute decabromodiphenyl ethane (DBDPE) are heavily used in various industrial products as flame retardant. They have been found to be persistent in the environment and have adverse health effects in humans. Although some former studies have reported toxic effects of BDE-209, the study of DBDPE's toxic effects is still in its infancy, and the effects of DBDPE on hepatotoxicity are also unclear. This study aimed to evaluate and compare the hepatotoxicity induced by BDE-209 and DBDPE using a rat model. Sprague-Dawley rats were administered DBDPE or BDE-209 (5, 50, 500 mg/kg bodyweight) intragastrically once a day for 28 days. Twenty-four hours after the end of treatment, the rats were sacrificed, and body liver weight, blood biochemical parameters, liver pathology, oxidative stress, inflammation, pregnane X receptor (PXR), constitutive androstane receptor (CAR), and changes in cytochrome P450 (CYP3A) enzymes were measured. Our results showed that both BDE-209 and DBDPE could cause liver morphological changes, induce oxidative stress, increase γ-glutamyl transferase and glucose levels in serum, and down-regulate PXR, CAR, and CYP3A expression. In addition, BDE-209 was found to increase liver weight and the ratio of liver/body weight, lead to elevated total bilirubin and indirect bilirubin levels in serum, and induce inflammation. The present study indicated that BDE-209 and DBDPE may interfere with normal metabolism in rats through oxidative stress and inflammation, which inhibit PXR and CAR to induce the expression of CYP3A enzymes, and finally produce hepatotoxic effects and cause liver damage in rats. Comparatively, our results show that the damage caused by BDE-209 was more serious than that caused by DBDPE.
Collapse
Affiliation(s)
- Yanmin Sun
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Yuwei Wang
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Baolu Liang
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Tian Chen
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Dan Zheng
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Xuezhen Zhao
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Li Jing
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China.
| | - Xianqing Zhou
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Zhiwei Sun
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China
| | - Zhixiong Shi
- School of Public Health and Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, China.
| |
Collapse
|
6
|
Luo J, Yang X, Qiu S, Li X, Xiang E, Fang Y, Wang Y, Zhang L, Wang H, Zheng J, Guo Y. Sex difference in monocrotaline-induced developmental toxicity and fetal hepatotoxicity in rats. Toxicology 2019; 418:32-40. [PMID: 30825512 DOI: 10.1016/j.tox.2019.02.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Revised: 02/20/2019] [Accepted: 02/25/2019] [Indexed: 12/15/2022]
Abstract
Pyrrolizidine alkaloids (PAs) are a class of hepatic toxins widely existing in plants. Cytochromes P450 (CYP) mediates PA bioactivation and toxicities in mammals. It has been reported that PAs can induce developmental toxicity, but systematic research is lacking. In this study, we investigated developmental toxicity of monocrotaline (MCT) in rats. Pregnant rats were administered with MCT (20 mg/kg) intragastrically from gestation day 9 to 20, followed by determination of changes in fetal growth, hepatic morphology, serum biochemical indices, and indicators of hepatocytes apoptosis. MCT was found to induce developmental toxicity and fetal hepatotoxicity, particularly in female fetuses. Metabolic activation was also studied by examination of bioactivation efficiency of MCT in fetal liver microsomes, serum MCT, pyrrole-protein adduction derived from MCT, and hepatic CYP3 A expression of fetuses in vivo. Male fetuses showed greater basal MCT bioactivation than that of female fetuses, but continuous exposure to MCT caused a selective CYP3 A induction in female fetuses, which may contribute to the sex difference in MCT-induced developmental toxicity.
Collapse
Affiliation(s)
- Jinyuan Luo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Xiaojing Yang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, People's Republic of China.
| | - Shuaikai Qiu
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Xia Li
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - E Xiang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Yan Fang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Yanqing Wang
- Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China.
| | - Li Zhang
- Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China.
| | - Hui Wang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Jiang Zheng
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, People's Republic of China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China; Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
| | - Yu Guo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| |
Collapse
|
7
|
Li X, Yang X, Xiang E, Luo J, Qiu S, Fang Y, Zhang L, Guo Y, Zheng J, Wang H. Maternal-Fetal Disposition and Metabolism of Retrorsine in Pregnant Rats. Drug Metab Dispos 2018; 46:422-428. [PMID: 29352068 DOI: 10.1124/dmd.117.079186] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 01/17/2018] [Indexed: 11/22/2022] Open
Abstract
Pyrrolizidine alkaloids (PAs) are extensively synthesized by plants, are commonly present in herbs and foodstuffs, and exhibit hepatotoxicity requiring metabolic activation by cytochrome P450 3A to form the electrophilic metabolites-pyrrolic esters. PAs also cause embryo toxicity, but the metabolic profiles of PAs in fetus and placenta have been far from clear. In this study, we determined the basal metabolic activation of retrorsine (RTS) in rat maternal liver, placenta, and fetal liver in vitro and examined the fetal toxicity and bioactivation of RTS in vivo. Detection of microsomal RTS metabolites in vitro showed that the basal metabolic activity of fetal liver and placenta to RTS was much weaker than that of maternal liver. In addition, a higher rate of pyrrolic ester formation was found in normal male fetal liver compared with that of female pups. In vivo exposure to RTS caused fetal growth retardation, as well as placental and fetal liver injury. Little difference in serum RTS was observed in dams and fetuses, but the content of pyrrole-protein adduction in the fetal liver was much lower than that in maternal liver, which was consistent with basal metabolic activity. Unexpectedly, compared with basal metabolism in fetal liver, exposure to RTS during middle and late pregnancy caused an opposite gender difference in RTS metabolism and CYP3A expression in the fetal liver. For the first time, our study showed that RTS can permeate the placenta barrier and entering fetal circulation, whereas the intrauterine pyrrolic metabolite was generated mainly by fetal liver but not transported from the maternal circulation. Induction of CYP3A by RTS was gender-dependent in the fetal liver, which was probably responsible for RTS-induced fetal hepatic injury, especially for female pups.
Collapse
Affiliation(s)
- Xia Li
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Xiaojing Yang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - E Xiang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Jinyuan Luo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Shuaikai Qiu
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Yan Fang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Li Zhang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Yu Guo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Jiang Zheng
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Hui Wang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| |
Collapse
|
8
|
Gabbia D, Pozza AD, Albertoni L, Lazzari R, Zigiotto G, Carrara M, Baldo V, Baldovin T, Floreani A, Martin SD. Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World J Gastroenterol 2017; 23:7519-7530. [PMID: 29204052 PMCID: PMC5698245 DOI: 10.3748/wjg.v23.i42.7519] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 09/18/2017] [Accepted: 10/17/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To ascertain whether cholestasis affects the expression of two CYP3A isoforms (CYP3A1 and CYP3A2) and of pregnane X receptor (PXR) and constitutive androstane receptor (CAR).
METHODS Cholestasis was induced by bile duct ligation in 16 male Wistar rats; whereas 8 sham-operated rats were used as controls. Severity of cholestasis was assessed on histological examination of liver sections, and serum concentrations of albumin, AST, ALT, GGT, ALPK and bilirubin. Gene and protein expressions of PXR, CAR, CYP3A1 and CYP3A2 were assessed by means of qRT-PCR and Western blot, respectively. Alterations in CYP3A activity were measured by calculating the kinetic parameters of 4-OH and 1’-OH-midazolam hydroxylation, marker reactions for CYP3A enzymes.
RESULTS The mRNA and protein expression of CYP3A1 increased significantly in mild cholestasis (P < 0.01). At variance, mRNA and protein expression of CYP3A2 didn’t change in mild cholestasis, whereas the expression and activity of both CYP3A1 and CYP3A2 decreased dramatically when cholestasis became severe. Consistently with these observations, the nuclear expression of both PXR and CAR, which was measured because they both translocate into the cell nucleus after their activation, virtually disappeared in the late stage of cholestatic injury, after an initial increase. These results indicate that early- and late-stage cholestasis affects CYP3A-mediated drug metabolism differently, probably as consequence of the different activation of PXR and CAR.
CONCLUSION Early- and late-stage cholestasis affects CYP3A-mediated drug metabolism differently. PXR and CAR might be targeted therapeutically to promote CYP3A-mediated liver detoxification.
Collapse
Affiliation(s)
- Daniela Gabbia
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Arianna Dalla Pozza
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Laura Albertoni
- Department of Medicine, General Pathology and Cytopathology Unit, University of Padova, Padova 35131, Italy
| | - Roberta Lazzari
- Department of Cardiac, Thoracic, and Vascular Sciences, Hygiene and Public Health Unit, University of Padova, Padova 35131, Italy
| | - Giorgia Zigiotto
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Maria Carrara
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Vincenzo Baldo
- Department of Cardiac, Thoracic, and Vascular Sciences, Hygiene and Public Health Unit, University of Padova, Padova 35131, Italy
| | - Tatjana Baldovin
- Department of Cardiac, Thoracic, and Vascular Sciences, Hygiene and Public Health Unit, University of Padova, Padova 35131, Italy
| | - Annarosa Floreani
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova 35131, Italy
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| |
Collapse
|
9
|
Abstract
Sex, the states of being female or male, potentially interacts with all xenobiotic exposures, both inadvertent and deliberate, and influences their toxicokinetics (TK), toxicodynamics, and outcomes. Sex differences occur in behavior, exposure, anatomy, physiology, biochemistry, and genetics, accounting for female-male differences in responses to environmental chemicals, diet, and pharmaceuticals, including adverse drug reactions (ADRs). Often viewed as an annoying confounder, researchers have studied only one sex, adjusted for sex, or ignored it. Occupational epidemiology, the basis for understanding many toxic effects in humans, usually excluded women. Likewise, Food and Drug Administration rules excluded women of childbearing age from drug studies for many years. Aside from sex-specific organs, sex differences and sex × age interactions occur for a wide range of disease states as well as hormone-influenced conditions and drug distribution. Women have more ADRs than men; the classic sex hormone paradigm (gonadectomy and replacement) reveals significant interaction of sex and TK including absorption, distribution, metabolisms, and elimination. Studies should be designed to detect sex differences, describe the mechanisms, and interpret these in a broad social, clinical, and evolutionary context with phenomena that do not differ. Sex matters, but how much of a difference is needed to matter remains challenging.
Collapse
Affiliation(s)
- Michael Gochfeld
- Environmental and Occupational Health Sciences Institute and Consortium for Risk Evaluation with Stakeholder Participation at Rutgers—Robert Wood Johnson Medical School. Piscataway, New Jersey
| |
Collapse
|
10
|
Rysz M, Bromek E, Haduch A, Sadakierska-Chudy A, Daniel WA. Damage to the Brain Serotonergic System Increases the Expression of Liver Cytochrome P450. Drug Metab Dispos 2015; 43:1345-52. [DOI: 10.1124/dmd.115.064980] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 06/09/2015] [Indexed: 01/16/2023] Open
|
11
|
De Martin S, Gabbia D, Albertin G, Sfriso MM, Mescoli C, Albertoni L, Paliuri G, Bova S, Palatini P. Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. Drug Metab Dispos 2014; 42:1617-26. [PMID: 25030308 DOI: 10.1124/dmd.114.058511] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Conflicting results have been obtained by clinical studies investigating the effect of liver cirrhosis on enzyme induction. Because ethical concerns do not give consent for methodologically rigorous studies in humans, we addressed this question by examining the effect of the prototypical inducer dexamethasone (DEX) on the pregnane X receptor (PXR)-mediated induction of CYP3A1 and 3A2 in a validated animal model of liver cirrhosis obtained by exposure of rats to carbon tetrachloride. For this purpose, we assessed mRNA levels, protein expressions, and enzymatic activities of both CYP3A enzymes, as well as mRNA and protein expressions of PXR in rat populations rigorously stratified according to the severity of liver insufficiency. Constitutive mRNA and protein expressions of CYP3A1 and CYP3A2 and their basal enzyme activities were not affected by liver dysfunction. DEX treatment markedly increased steady-state mRNA level, protein content, and enzymatic activity of CYP3A1 in healthy and cirrhotic rats, irrespective of the degree of liver dysfunction. On the contrary, the inducing effect of DEX on gene and protein expressions and enzyme activity of CYP3A2 was preserved in moderate liver insufficiency, whereas it was greatly curtailed when liver insufficiency became severe. mRNA and protein expressions of PXR were neither reduced by liver dysfunction nor increased by DEX treatment. These results indicate that even the inducibility of cytochrome P450 isoforms under the transcriptional control of the same nuclear receptor may be differentially affected by cirrhosis and may partly explain why conflicting results were obtained by human studies.
Collapse
Affiliation(s)
- Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Daniela Gabbia
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Giovanna Albertin
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Maria Martina Sfriso
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Claudia Mescoli
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Laura Albertoni
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Giovanna Paliuri
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Sergio Bova
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| | - Pietro Palatini
- Department of Pharmaceutical and Pharmacological Sciences (S.D.M., D.G., G.P., S.B., P.P.), Department of Molecular Medicine, Section of Anatomy (G.A., M.M.S.), and Department of Medicine, Surgical Pathology and Cytopathology Unit (C.M., L.A.), University of Padova, Padova, Italy
| |
Collapse
|
12
|
Smolarek AK, So JY, Thomas PE, Lee HJ, Paul S, Dombrowski A, Wang CX, Saw CLL, Khor TO, Kong ANT, Reuhl K, Lee MJ, Yang CS, Suh N. Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia. Mol Carcinog 2012; 52:514-25. [PMID: 22389237 DOI: 10.1002/mc.21886] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Revised: 01/26/2012] [Accepted: 01/26/2012] [Indexed: 12/31/2022]
Abstract
Previous clinical and epidemiological studies of vitamin E have used primarily α-tocopherol for the prevention of cancer. However, γ-tocopherol has demonstrated greater anti-inflammatory and anti-tumor activity than α-tocopherol in several animal models of cancer. This study assessed the potential chemopreventive activities of a tocopherol mixture containing 58% γ-tocopherol (γ-TmT) in an established rodent model of mammary carcinogenesis. Female ACI rats were utilized due to their sensitivity to 17β-estradiol (E2 ) to induce mammary hyperplasia and neoplasia. The rats were implanted subcutaneously with sustained release E2 pellets and given dietary 0.3% or 0.5% γ-TmT for 2 or 10 wk. Serum E2 levels were significantly reduced by the treatment with 0.5% γ-TmT. Serum levels of inflammatory markers, prostaglandin E2 and 8-isoprostane, were suppressed by γ-TmT treatment. Histology of mammary glands showed evidence of epithelial hyperplasia in E2 -treated rats. Immunohistochemical analysis of the mammary glands revealed a decrease in proliferating cell nuclear antigen (PCNA), cyclooxygenase-2 (COX-2), and estrogen receptor α (ERα), while there was an increase in cleaved-caspase 3, peroxisome proliferator-activated receptor γ (PPARγ), and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in γ-TmT-treated rats. In addition, treatment with γ-TmT resulted in a decrease in the expression of ERα mRNA, whereas mRNA levels of ERβ and PPARγ were increased. In conclusion, γ-TmT was shown to suppress inflammatory markers, inhibit E2 -induced cell proliferation, and upregulate PPARγ and Nrf2 expression in mammary hyperplasia, suggesting that γ-TmT may be a promising agent for human breast cancer prevention.
Collapse
Affiliation(s)
- Amanda K Smolarek
- Department of Pharmacology and Toxicology, Rutgers, The State University of New Jersey, Piscataway, New Jersey
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, Wang G, Chen X. Effects of Short-Term and Long-Term Pretreatment of Schisandra Lignans on Regulating Hepatic and Intestinal CYP3A in Rats. Drug Metab Dispos 2009; 37:2399-407. [DOI: 10.1124/dmd.109.027433] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
14
|
Kania-Korwel I, Hrycay EG, Bandiera SM, Lehmler HJ. 2,2',3,3',6,6'-Hexachlorobiphenyl (PCB 136) atropisomers interact enantioselectively with hepatic microsomal cytochrome P450 enzymes. Chem Res Toxicol 2008; 21:1295-303. [PMID: 18494506 DOI: 10.1021/tx800059j] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
2,2',3,3',6,6'-Hexachlorobiphenyl (PCB 136) is a chiral and highly neurotoxic PCB congener of environmental relevance. (+)-PCB 136 was previously shown to be enriched in tissues from mice treated with racemic PCB 136. We investigated the spectral interactions of (+)-, (-)-, and (+/-)-PCB 136 with mouse and rat hepatic microsomal cytochrome P450 (P450) enzymes to test the hypothesis that enantioselective binding to specific P450 enzymes causes the enrichment of (+)-PCB 136 in vivo. Hepatic microsomes prepared from C57BL/6 mice or Long Evans rats treated with beta-naphthoflavone or 3-methylcholanthrene, phenobarbital, and dexamethasone (prototypical inducers of CYP1A, CYP2B, and CYP3A, respectively) were used to determine first, whether the (+)-PCB 136 atropisomer binds to hepatic microsomal P450 enzymes to a greater extent than does the (-)-PCB 136 atropisomer and second, whether P450 enzymes of one subfamily bind the two PCB 136 atropisomers more efficiently than do P450 enzymes of other subfamilies. Increasing concentrations of (+)-, (-)-, or (+/-)-PCB 136 were added to hepatic microsomes, and the difference spectrum and maximal absorbance change, a measure of PCB binding to P450 enzymes, were measured. A significantly larger absorbance change was observed with (+)-PCB 136 than with (-)-PCB 136 with all four hepatic microsomal preparations in mice and rats, indicating that (+)-PCB 136 interacted with microsomal P450 enzymes to a greater degree than did (-)-PCB 136. In addition, binding of the PCB 136 atropisomers was greatest in microsomes from PB-treated mice and rats and was inhibited by CYP2B antibodies, indicating the involvement of CYP2B enzymes. Together, these results suggest preferential binding of (+)-PCB 136 to P450 enzymes (such as CYP2B and CYP3A) in hepatic microsomes, an observation that may explain the enantioselective enrichment of the (+)-PCB 136 atropisomer in tissues of mice.
Collapse
Affiliation(s)
- Izabela Kania-Korwel
- Department of Occupational and Environmental Health, University of Iowa, 100 Oakdale Campus #124 IREH, Iowa City, Iowa 52242, USA
| | | | | | | |
Collapse
|
15
|
Edwards PR, Hrycay EG, Bandiera SM. Differential inhibition of hepatic microsomal alkoxyresorufin O-dealkylation activities by tetrachlorobiphenyls. Chem Biol Interact 2007; 169:42-52. [PMID: 17586480 DOI: 10.1016/j.cbi.2007.05.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2007] [Revised: 05/11/2007] [Accepted: 05/14/2007] [Indexed: 11/29/2022]
Abstract
Polychlorinated biphenyls (PCBs) elicit a spectrum of biochemical and toxic effects in exposed animals. In the present study, we assessed the effect of PCB structure, using four symmetrically-substituted PCBs, on cytochrome P450 (CYP)-mediated methoxy-, ethoxy- and benzyloxyresorufin O-dealkylase (MROD, EROD and BROD, respectively) activities. We found that 2,2',4,4'-tetrachlorobiphenyl (PCB 47), 2,2',5,5'-tetrachlorobiphenyl (PCB 52), 2,2',6,6'-tetrachlorobiphenyl (PCB 54) and 3,3',4,4'-tetrachlorobiphenyl (PCB 77) inhibited alkoxyresorufin O-dealkylase activities in hepatic microsomes from 3-methylcholanthrene (MC) or phenobarbital (PB)-treated rats. Measurement of the in vitro inhibitory potencies of the tetrachlorobiphenyls revealed that MROD, EROD and BROD activities were differentially inhibited and the degree of inhibition was determined by the chlorination pattern of the PCB. PCB 77 was more potent than PCB 47 or PCB 52 at inhibiting MROD and EROD activities in hepatic microsomes from MC-treated rats, while no inhibition of either activity was observed with PCB 54. In contrast, BROD activity measured in hepatic microsomes from PB-treated rats was inhibited by PCB 47, PCB 52 and PCB 54 but not by PCB 77. The mode of inhibition for each activity was also evaluated statistically. Inhibition of the alkoxyresorufin O-dealkylase activities could not be discerned in hepatic microsomes from corn oil-treated rats because the activities were inherently too low. No evidence for mechanism-based inhibition of MROD, EROD or BROD activities or an effect via CYP reductase was found. The results demonstrate that relatively coplanar PCBs such as PCB 77 preferentially inhibit EROD and MROD activities, whereas noncoplanar PCBs such as PCB 54 preferentially inhibit BROD activity.
Collapse
Affiliation(s)
- Patrick R Edwards
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
| | | | | |
Collapse
|